These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14383121)

  • 1. [An experiment in treatment of an estrogen resistant prostate carcinoma with male hormones].
    SCHULZE W
    Medizinische; 1955 Apr; 17():654-5. PubMed ID: 14383121
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improvement of medicaments in estrogen-resistant prostate carcinoma].
    BALVERS AG
    Ned Tijdschr Geneeskd; 1958 Sep; 102(38):1891-2. PubMed ID: 13600471
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prostate carcinoma treated with male hormones].
    SCHULZE W
    Z Urol; 1954; Spec Issue():405-9. PubMed ID: 14360450
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
    Carruba G
    J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of the study of calcium metabolism in carcinoma of the breast and prostate before and after various endocrine treatments].
    MOLINATTI GM; CAMANNI F; OLIVETTI M
    Presse Med (1893); 1959 Jan; 67(5):182-5. PubMed ID: 13633839
    [No Abstract]   [Full Text] [Related]  

  • 7. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.
    Rau KM; Kang HY; Cha TL; Miller SA; Hung MC
    Endocr Relat Cancer; 2005 Sep; 12(3):511-32. PubMed ID: 16172190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
    Halland A; Jønler M; Pedersen KV
    Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.
    Mimeault M; Batra SK
    Carcinogenesis; 2006 Jan; 27(1):1-22. PubMed ID: 16195239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex steroid hormone metabolism and prostate cancer.
    Soronen P; Laiti M; Törn S; Härkönen P; Patrikainen L; Li Y; Pulkka A; Kurkela R; Herrala A; Kaija H; Isomaa V; Vihko P
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):281-6. PubMed ID: 15663991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of prostatic cancer stage T3N0M0].
    Loran OB; Tomkevich BA
    Urologiia; 2004; (5):65-7. PubMed ID: 15560169
    [No Abstract]   [Full Text] [Related]  

  • 12. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    Platz EA; Giovannucci E
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
    Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
    Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes.
    Hartel A; Didier A; Ulbrich SE; Wierer M; Meyer HH
    J Steroid Biochem Mol Biol; 2004 Oct; 92(3):187-97. PubMed ID: 15555912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid androgen cycling as treatment for patients with prostate cancer.
    Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
    Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate.
    Whittington K; Connors B; King K; Assinder S; Hogarth K; Nicholson H
    Prostate; 2007 Jul; 67(10):1132-42. PubMed ID: 17492653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidimensional approaches in dealing with prostate cancer.
    Ali S; Ali S
    Gene; 2008 Feb; 410(1):1-8. PubMed ID: 18226472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ; Burgenson J; Hild SA; Reel JR
    Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.